Atria Wealth Solutions Inc. Sells 881 Shares of Insmed, Inc. $INSM

Atria Wealth Solutions Inc. lessened its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 15.9% in the second quarter, Holdings Channel reports. The institutional investor owned 4,662 shares of the biopharmaceutical company’s stock after selling 881 shares during the period. Atria Wealth Solutions Inc.’s holdings in Insmed were worth $469,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. increased its position in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 221 shares in the last quarter. ORG Partners LLC increased its position in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 196 shares in the last quarter. Hilltop National Bank bought a new position in Insmed during the 2nd quarter valued at approximately $28,000. LRI Investments LLC bought a new position in Insmed during the 2nd quarter valued at approximately $59,000. Finally, Signaturefd LLC increased its holdings in shares of Insmed by 60.0% in the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 325 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have recently weighed in on INSM. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Wednesday, October 8th. The Goldman Sachs Group upped their target price on shares of Insmed from $121.00 to $196.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Morgan Stanley upped their target price on shares of Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Wells Fargo & Company upped their target price on shares of Insmed from $140.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, September 3rd. Finally, Evercore ISI restated an “outperform” rating and set a $180.00 target price on shares of Insmed in a research note on Wednesday, October 1st. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $152.88.

Insmed Stock Performance

Shares of INSM opened at $165.76 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed, Inc. has a one year low of $60.40 and a one year high of $166.44. The firm has a market capitalization of $35.04 billion, a P/E ratio of -29.03 and a beta of 1.03. The business has a fifty day moving average of $143.38 and a 200 day moving average of $105.27.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. During the same period in the previous year, the firm earned ($1.94) EPS. The business’s revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Buying and Selling

In related news, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the completion of the sale, the chief operating officer owned 105,637 shares of the company’s stock, valued at $13,477,168.46. The trade was a 19.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of Insmed stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.45, for a total value of $11,129,834.00. Following the transaction, the insider owned 36,461 shares in the company, valued at $5,303,252.45. This trade represents a 67.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 152,657 shares of company stock valued at $21,442,198 over the last ninety days. 3.00% of the stock is owned by insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.